EBS241220P11000
- 1.80
- 0.000.00%
Emergent BioSolutions Newsroom
Emergent BioSolutions Wins $50 Million Contract Option for Cyfendus; Shares Rise
Express News | Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
Express News | Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted)
Investors Don't See Light At End Of Emergent BioSolutions Inc.'s (NYSE:EBS) Tunnel And Push Stock Down 26%
Emergent BioSolutions Inc.'s (NYSE:EBS) Institutional Investors Lost 11% Last Week but Have Benefitted From Longer-term Gains
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern
First Mpox Case Linked to African Outbreak Reported in U.S.
Have Emergent BioSolutions Insiders Been Selling Stock?
US Manufacturing Index Rises To 43, Highest Since 2020
Vaccines Makers Close Lower on Reports RFK Jr May Head HHS
Emergent Biosolutions Insider Sold Shares Worth $272,750, According to a Recent SEC Filing
Emergent BioSolutions (NYSE:EBS) Has Debt But No Earnings; Should You Worry?
India's Business Standard Reported New Study Claims Mpox Clade La Has Evolved To Spread From Human To Human, Citing October 24 Uploaded Paper On Virologica
Emergent Software Welcomes Industry Leader Marc Kermisch as Chief Technology Officer
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
Emergent Biosolutions Shares Surge 28% After Swinging to 3Q Profit
Gold Gains 1%; Halliburton Posts Weak Q3 Results
Emergent BioSolutions | 10-Q: Q3 2024 Earnings Report